Olymvax Biopharmaceuticals: Shanghai Wushan has reduced its holdings by 3.00%

Olymvax Biopharmaceuticals announced that its controlling shareholder, Shanghai Wushan, originally planned to reduce its holdings by no more than 12.178 million shares through centralized bidding and block trading from August 13 to November 12, 2025. As of October 31, 4.0593 million shares were reduced through centralized bidding and 8.1187 million shares through block trading, totaling 12.178 million shares, accounting for 3.00% of the total share capital, with transaction prices ranging from 19.28 to 30.67 yuan, cashing out 279 million yuan; it currently holds 60.2163 million shares, accounting for 14.83%, and the reduction plan has been completed

Olymvax Biopharmaceuticals: Net profit in the third quarter was 34.2829 million yuan, a year-on-year increase of 7.22%

Olymvax Biopharmaceuticals announced that its revenue for the third quarter was 201 million yuan, a year-on-year increase of 25.38%; net profit was 34.2829 million yuan, a year-on-year increase of 7.22%. Revenue for the first three quarters was 507 million yuan, a year-on-year increase of 31.11%; net profit was 47.4798 million yuan, a year-on-year increase of 1,079.36%

A-share innovative drug concept stocks fluctuated lower, with BETTA PHARMACEUTICALS falling over 10%, Jincheng Pharm, Konruns, Baillie Tianheng, Olymvax Biopharmaceuticals, and CCHT all dropping more than 5%

Chengdu Olymvax Biopharmaceuticals major shareholder reduces holdings, equity change reaches 1% threshold

Chengdu Olymvax Biopharmaceuticals Co., Ltd. announced that its controlling shareholder Shanghai Wushan Biotechnology Co., Ltd. and its concerted actors Fan Shaowen and Fan Fan's equity changes have reached the 1% threshold. From September 4 to 29, 2025, Shanghai Wushan reduced its shareholding through centralized bidding and block trading, with its shareholding ratio decreasing from 29.00% to 27.92%. This reduction is to fulfill a previous plan and will not affect the changes in the controlling shareholder and actual controller, nor will it impact the company's governance and operations

Olymvax Biopharmaceuticals plans to issue H shares and list on the Hong Kong Stock Exchange

According to the Zhitong Finance APP, Olymvax Biopharmaceuticals announced that the company is planning to issue overseas shares (H shares) and apply for listing on the Hong Kong Stock Exchange (referred to as "Hong Kong Stock Exchange") to deepen its international strategic layout, enhance international visibility and influence, further optimize its capital structure, and strengthen its overall competitive strength